Novasep & GTP join forces to ease production of mAbs and proteins
Published on 2016-03-21
The partnership offers biotech firms full CDMO services at all process development stages, from gene to end product.
Lyon and Toulouse, France, March 21, 2016 – Novasep, a leading supplier of services and technologies for the life sciences industry, and GTP (Gene-to-Proteins) Technology, a CDMO providing recombinant protein and process development services, today announce a partnership that combines their expertise in monoclonal antibodies (mAbs) production. The partners aim to facilitate the development of therapeutic and diagnostic candidates for European biopharmaceutical clients.